Table 1.
Patient characteristics
| Number of patients | 13 |
|---|---|
| Median age (years) | 67 |
| Sex, n (%): | |
| - Male: | 9 (69) |
| - Female: | 4 (31) |
| ECOG performance status, n (%): | |
| - 0 | 10 (77) |
| - 1 | 3 (23) |
| Number of [18F]FB-IL2-PET scans per patient, n (%): | |
| - 1 | 2 (15) |
| - 2 | 11 (85) |
| Immunotherapy regimen, n (%): | |
| - Nivolumab | 5 (38) |
| - Pembrolizumab | 7 (54) |
| - Ipilimumab + nivolumab | 1 (8) |
| RECIST v1.1 response, n (%): | |
| - Complete response | 1 (10) |
| - Partial response | 1 (10) |
| - Stable disease | 2 (20) |
| - Progressive disease | 6 (60) |
Abbreviations used: ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid Tumors